With Mav­er­ick now in Takeda's hands, James Sci­bet­ta turns the page; Roivant CMO leaves in fa­vor of small IL-2 biotech

→ An­oth­er CEO op­por­tu­ni­ty has pre­sent­ed it­self for James Sci­bet­ta, the chief ex­ec­u­tive of Mav­er­ick Ther­a­peu­tics when Take­da ponied up $525 mil­lion in March to buy its T cell col­lab­o­ra­tor and in­te­grate the staff in­to the R&D unit. Sci­bet­ta has signed on as CEO of an­ti­body start­up Im­muneID, co-found­ed and chaired by Long­wood Fund’s Christoph West­phal with tech com­ing from Stephen Elledge’s lab at Har­vard. So ends a fleet­ing CEO tenure for David Don­abe­di­an, who will stay close by as an ad­vi­sor. Sci­bet­ta, the CFO and lat­er pres­i­dent of Paci­ra Phar­ma­ceu­ti­cals un­til he joined Mav­er­ick in 2017, steps for­ward to lead a biotech that’s chalked up $70 mil­lion in fi­nanc­ing, in­clud­ing $50 mil­lion in a Se­ries A this sum­mer.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN